The Carolina Nanoformulation Workshop and the Nanomedicine Drug Delivery Symposium (nanoDDS) will jointly host a virtual meeting for 2020. The meeting will feature 3 days of lectures from distinguished speakers and daily roundtable discussions. The meeting is supported by the CNDD (Center for Nanotechnology in Drug Delivery).
During this CNW you will learn about:
- Cancer Immunotherapy
- Tumor Delivery
- Nanoformulation Characterization
- Promoting Diversity
- Research Funding
- Vaccines and Therapeutics for COVID-19
For more information and to register, please visit the event website.
Working at the nanoscale enables scientists to use unique physical, chemical, mechanical, and optical properties of materials. However, how can you work safely in a laboratory with products that contain nanomaterials?
Join Director of Environmental Safety Ken Kretchman of N.C. State University, Professor of Chemistry Craig Merlic of UCLA, Chemical and Laboratory Safety Officer Debbie Decker of UC Davis as well as moderator and Associate Director for Emerging Technologies Chuck Geraci of NIOSH, as they discuss the importance of managing products containing nanomaterials by integrating them into an existing lab safety program. During this free interactive broadcast, they will highlight the importance of a strong safety culture that is created and maintained by bench scientists who champion appropriate safety practices.
For more information and to register, visit the event website.
The 2018 U.S.-EU: Bridging NanoEHS Research Efforts joint workshop will bring together the U.S.- EU nanoEHS Communities of Research (CORs), which serve as a platform for American and European scientists to share information on nanoEHS research. This will be the 7th event in a series of joint nanoEHS workshops organized by the U.S. National Nanotechnology Initiative and the European Commission.
Click here to register now.
Visit workshop website or contact email@example.com for more details.
We are excited to announce that RTNN’s Dr. David Berube will serve as a member on the Risk Communication Advisory Committee for the Food and Drug Administration (FDA) beginning this October and spanning into the next administration. As a committee member, Dr. Berube will advise the FDA Commissioner on strategies to effectively communicate the risks and benefits of FDA-regulated products to the public. The committee is also tasked with reviewing and evaluating relevant research and facilitating the implementation of public communication programs.